Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT01727518
Other study ID # LEAD1
Secondary ID
Status Enrolling by invitation
Phase N/A
First received November 4, 2012
Last updated January 16, 2016
Start date October 2011
Est. completion date October 2023

Study information

Verified date January 2016
Source LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Contact n/a
Is FDA regulated No
Health authority Austria: Ethikkommission
Study type Observational

Clinical Trial Summary

The Austrian LEAD study is the first investigation initiated in Austria that aims to investigate the prevalence and the natural history of COPD in a reference population of Austria.


Description:

Chronic obstructive pulmonary disease (COPD) is one of the most important causes of morbidity and mortality worldwide and has a tremendous impact on the individual patient, the healthcare system, and the general public.

Contrary to other chronic diseases, the natural history of COPD, commonly described with the natural decline of lung function, has not been investigated sufficiently and the presence of various phenotypes is still under intensive investigation.

The investigators aim to study the natural course of lung function and the development of COPD in a longitudinal, observational, population based cohort in Austria.

Study population (male and female, age 6 - 80 years) will be randomly recruited via the national inhabitants register in both Vienna (urban cohort) and Lower Austria (rural cohort).

Health examinations will include lung function testing, cardiovascular examinations, body composition and metabolic testing as well as socioeconomic counseling. Furthermore, the initiation of a bio bank will provide serological testing on biomarker and epigenetic analysis.

In particular, the investigators intend to assess a) the age-related natural decline in lung function in the general population, b) the prevalence of COPD and the development of major respiratory symptoms in this disease, c) the prevalence of the most important COPD comorbidities (cardiovascular, metabolic and cognitive dysfunction) and d) the association between lung health and social status, individual long term exposure to air pollution and other toxic inhalants.

This health examination will be the first investigation in Austria providing information about the most prevalent respiratory disease and it`s comorbidities in a longitudinal approach.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 10000
Est. completion date October 2023
Est. primary completion date May 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Years to 80 Years
Eligibility Inclusion Criteria:

- Male and Female,

- Age 6 - 80 years,

- Invitation by study invitation letter

Exclusion Criteria:

- Insufficient language skills

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Austria The LEAD Study Center Vienna

Sponsors (1)

Lead Sponsor Collaborator
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of COPD in a general population of Austria The Burden of Obstructive Lung Disease (BOLD) Study revealed in 2007 a surprisingly high prevalence of COPD in Salzburg (26%) as compared to other European countries (about 10%), particularly in young women aged 40 to 59 years.
However, reliable data about the prevalence of COPD in Austria is lacking. Therefore, the aims are 1. To estimate the prevalence of COPD in the general population of Austria, 2. To explore if the prevalence of COPD is different in urban and rural environments and associated to risk factors as smoking, socioeconomic status (income, education, and occupation), diagnosis of asthma, and presence of allergy.
4 years No
Secondary Longitudinal study of the natural history of lung function growth and decline (NATHIS) Lung growths until the age of 15 in females and in the mid-20s in males and declines over time. Compared to female, lung function decline in male starts after a plateau phase and lung function decline is slightly higher compared to female.However, until now it is unclear if female smokers are more susceptible to the deleterious effects of tobacco smoking than male. Therefore, the aims are: 1.To investigate the natural history of lung function in a "healthy population" (defined by a population free of respiratory symptoms and/or disease, metabolic, cardiovascular and/or mental diseases) and to determine normal lung function growth and decline over time. 2.To investigate the influence of smoking, smoking cessation, air pollution (urban vs. rural), socioeconomic status (income, education, and occupation), allergy, bronchial hyperactivity and systemic inflammation on lung function growth and decline over time. 3.To identify the risk factors for accelerated decline of lung function. 12 years No
See also
  Status Clinical Trial Phase
Recruiting NCT03368612 - Comparative Study Between the AirGoTM System and Standard Tests in the Assessment of the Respiratory Function N/A
Recruiting NCT00530491 - Prospective Trial to Reduce Morbidity and Mortality After Lung Surgery in Patients With Reduced Pulmonary Capacity N/A
Completed NCT05267067 - Impact of Positive End Maximum Voluntary Ventilation and Dyspnea Index in Patients After Valvular Heart Surgery N/A
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Recruiting NCT06019949 - Spinal Cord Stimulation for Respiratory Rehabilitation in Patients With Chronic Spinal Cord Injury N/A
Completed NCT05098808 - Artificial Intelligence in Diagnosing Dysphagia Patients
Recruiting NCT03709199 - Long Term Follow up of Children Enrolled in the REDvent Study
Completed NCT01532180 - Safety and Efficacy of a Hypoglossal Nerve Implant for the Treatment of Obstructive Sleep Apnea (OSA) N/A
Terminated NCT00464490 - Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts N/A
Completed NCT00750074 - Slope of the Pressure-Time Waveform Predicts Resistance and Compliance in Mechanically Ventilated Subjects N/A
Completed NCT00202319 - Effectiveness of Sedation Management in an Australian Intensive Care Unit N/A
Completed NCT05270538 - Cardiorespiratory and Acid-basic Imbalance Caused by Use of Mask N/A
Terminated NCT02022072 - Evaluation of Vital Capacity Phase 2
Recruiting NCT05398068 - Effects of Exercise Training on Exercise Capacity and Sleep Quality in Patients With Obesity Hypoventilation Syndrome N/A
Completed NCT03327610 - Selecting the Best Ventilator Hyperinflation Settings N/A
Completed NCT00665405 - Atelectasis During Delivery - Comparing Cesarian (c) -Section and Labor N/A
Completed NCT00004424 - Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy N/A
Completed NCT04647383 - A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 1
Completed NCT01565954 - Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children
Terminated NCT00394550 - Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty N/A